Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$5.05
▲ $0.15 (+3.1%)
Market data updated: 09/19 07:26 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$190.57M
Day Range
$4.80 - $5.15
52-Week Range
$1.00 - $7.19
Beta
—
Next Earnings
10.11.2026
Support
$4.28
Resistance
$7.19
ANTX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+291.5% (1Y)
Strengths: 5/21 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 32.6%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 7.3% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
50
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
66
Quality
No data available
Value
50
Momentum
26
Risk
40
Sentiment
100
Fundamental
46
Institutional
7
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of AN2 Therapeutics highlights its progress in drug development, particularly for rare diseases like polycythemia vera and Chagas disease. The company presented clinical data at the SOHO 2026 conference, advanced its oral AN2-502998 candidate for Phase 2 trials, and reported positive preclinical and early human results. AN2 also saw financial improvements in Q2 2026, with reduced losses per share, and received a *Buy* rating with a $9 price target from Guggenheim. Leadership changes, including the appointment of a new Chief Medical Officer, were also noted.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about AN2 Therapeutics, Inc.. News trend score: 100. Reason: 9 of the last 14 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
44
🎯 Conviction (vs. Emotion)
50
Psychology
50
Fundamentals
46
Technical
26
Valuation
50
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+1%
Market Narrative
55
Fundamental Reality
50
Narrative Gap
+5
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a dominant euphoric state, where positive momentum, extreme sentiment, and a 29% deviation above the 200-day average align with speculative excitement. Overconfidence is present but secondary, as price gains outpace fundamentals. The narrative gap (15 points) hints at a disconnect between optimism and underlying metrics, but the data lacks clear signs of panic or anchoring. The key question is whether this momentum remains self-sustaining or if sentiment will correct when fundamentals fail to justify the rally.
Updated: 09/09/2026, 02:52 AM
What could change this?
👥 What the crowd believes
"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera"
"Guggenheim analyst initiates coverage on AN2 Therapeutics with a Buy rating and announces Price Target of $9"
"AN2 Therapeutics Says Chagas Disease Drug Shows Positive Preclinical, Early Human Data"
"AN2 Therapeutics reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with some models seeing resilience and others warning of speculative excess. Peter Lynch and Walter Bagehot both score it maximally—Lynch due to a lack of growth data (leaving him unable to form an opinion) and Bagehot for its strong liquidity, suggesting it could weather financial stress. Meanwhile, technical traders like Jesse Livermore and Jack Schwager offer mixed takes: Livermore sees a positive trend, while Schwager finds no clear edge, highlighting conflicting signals in price action. On the cautionary end, Grahamite investors (both strict and enterprising) dismiss it outright for failing valuation and defensive metrics, while behavioral economists like Mackay, Loeb, and Veblen flag it as a speculative bubble or growth-chasing trap. Even passive investors like Malkiel/Bogle and Marks question its merit, seeing it as either overvalued or late-cycle, while Housel’s near-zero score suggests it’s volatile enough to test even the most patient long-term holders.
Peter Lynch
One Up on Wall Street (1989)
🟢 100
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 95
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 68
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 46
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 43
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 41
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 28
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 25
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 18
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-66.3%
ROA
-56.8%
ROIC
—
EPS
-$1.16
Cash
$19.94M
Total Debt
—
Current Ratio
6.87
Debt/Equity
—
אין נתונים היסטוריים זמינים.
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$1.76
Tangible Book Value per Share (Tangible NAV)
$1.76
Sentiment based on basic keywords (not AI) — 9 positive, 5 neutral, 0 negative out of the last 14 articles.
Yahoo · 16.9.2026
Yahoo · 31.8.2026
Business Wire · 31.8.2026
Benzinga · 31.8.2026
Yahoo · 31.8.2026
GlobeNewswire · 31.8.2026
Business Wire · 24.8.2026
Benzinga · 13.8.2026
Business Wire · 11.8.2026
Benzinga · 11.8.2026
Benzinga · 20.7.2026
MT Newswires · 4.6.2026
Business Wire · 4.6.2026
MT Newswires · 14.5.2026
AN2 Therapeutics, Inc. (ANTX) currently has a StockIQ AI score of 50/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ANTX currently scores 50/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ANTX's technical score is 26/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 32.6%; Net income growth: 31.5%; Current ratio: 6.87.
Based on the real signals StockIQ computed: ATR: 7.3% of price; Calmar: -0.29 (3y annualized return -28.1% / max drawdown 95.4%); Return on equity (ROE): -66.3% (negative).
StockIQ has no recorded dividend payment history for ANTX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 1 purchases and 13 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Readnour Robin Shane | Open Market Sale | 9.9.2026 | 523 | -523 | $6.02 |
| Readnour Robin Shane | Open Market Sale | 9.9.2026 | 585 | -585 | $6.02 |
| Readnour Robin Shane | Open Market Sale | 8.9.2026 | 4,725 | -4,725 | $6.02 |
| Readnour Robin Shane | Open Market Sale | 8.9.2026 | 5,294 | -5,294 | $6.02 |
| Readnour Robin Shane | Open Market Sale | 3.9.2026 | 2,877 | -2,877 | $6.07 |
| Readnour Robin Shane | Open Market Sale | 3.9.2026 | 3,223 | -3,223 | $6.07 |
| Williams Sarah Joanne | Open Market Sale | 1.9.2026 | 272 | -272 | $5.53 |
| FitzPatrick Margaret M | Open Market Purchase | 1.9.2026 | 2,098 | +2,098 | $5.53 |
| Readnour Robin Shane | Open Market Sale | 17.8.2026 | 18,706 | -18,706 | $6.01 |
| Readnour Robin Shane | Open Market Sale | 17.8.2026 | 16,696 | -16,696 | $6.01 |
| Zakrzewski Joseph S | Gift | 14.8.2026 | 0 | -405,880 | — |
| Zakrzewski Joseph S | Gift | 14.8.2026 | 405,880 | -405,880 | — |
| Marks Gilbert Lynn | Grant/Award from Employer | 10.7.2026 | 2,789 | +2,789 | — |
| Aziz Kabeer | Grant/Award from Employer | 10.7.2026 | 2,852 | +2,852 | — |
| Martin Patricia A. | Grant/Award from Employer | 10.7.2026 | 766 | +766 | — |
| Martin Patricia A. | Grant/Award from Employer | 10.7.2026 | 18,863 | +766 | — |
| Marks Gilbert Lynn | Grant/Award from Employer | 10.7.2026 | 81,873 | +2,789 | — |
| Aziz Kabeer | Grant/Award from Employer | 10.7.2026 | 59,106 | +2,852 | — |
| Eizen Joshua M | Open Market Sale | 8.7.2026 | 5,945 | -5,945 | $4.17 |
| Eizen Joshua M | Open Market Sale | 8.7.2026 | 206,554 | -5,945 | $4.17 |
| Williams Sarah Joanne | Open Market Sale | 29.5.2026 | 265 | -265 | $4.43 |
| Williams Sarah Joanne | Open Market Sale | 29.5.2026 | 66,583 | -265 | $4.43 |
| Aziz Kabeer | Grant/Award from Employer | 10.4.2026 | 3,775 | +3,775 | — |
| Martin Patricia A. | Grant/Award from Employer | 10.4.2026 | 1,192 | +1,192 | — |
| Marks Gilbert Lynn | Grant/Award from Employer | 10.4.2026 | 3,775 | +3,775 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,507,571 shares short as of 2026-08-31 · vs. 2,377,829 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
65.3% of trading volume this week was short selling, vs. 48.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology